Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
Bronstein, Gewirtz & Grossman, is investigating potential claims against Liquidia Technologies, Inc. (NASDAQ:LQDA) on behalf of its shareholders. The investigation follows Liquidia's announcement on August 19, 2024, that the FDA granted tentative approval for YUTREPIA™, their inhalation powder for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, final approval is delayed due to a competing product's regulatory exclusivity. This news caused Liquidia's stock price to drop 30.62%, closing at $9.79 per share. Shareholders are encouraged to assist in the investigation and can contact the firm for more information.
Bronstein, Gewirtz & Grossman sta indagando su potenziali reclami contro Liquidia Technologies, Inc. (NASDAQ:LQDA) per conto dei suoi azionisti. L'indagine segue l'annuncio di Liquidia del 19 agosto 2024, che la FDA ha concesso approvazione preliminare per YUTREPIA™, il loro polvere inalatoria per il trattamento dell'ipertensione arteriosa polmonare e dell'ipertensione polmonare associata a malattie polmonari interstiziali. Tuttavia, l'approvazione finale è in ritardo a causa dell'esclusività normativa di un prodotto concorrente. Questa notizia ha causato un calo del prezzo delle azioni di Liquidia del 30,62%, chiudendo a $9,79 per azione. Si incoraggiano gli azionisti a partecipare all'indagine e possono contattare lo studio per ulteriori informazioni.
Bronstein, Gewirtz & Grossman está investigando posibles reclamaciones contra Liquidia Technologies, Inc. (NASDAQ:LQDA) en nombre de sus accionistas. La investigación sigue el anuncio de Liquidia del 19 de agosto de 2024, en el que la FDA otorgó aprobación tentativa para YUTREPIA™, su polvo de inhalación para tratar la hipertensión arterial pulmonar y la hipertensión pulmonar asociada con enfermedades pulmonares intersticiales. Sin embargo, la aprobación final se ha retrasado debido a la exclusividad reglamentaria de un producto competidor. Esta noticia provocó que el precio de las acciones de Liquidia cayera un 30,62%, cerrando a $9,79 por acción. Se alienta a los accionistas a colaborar en la investigación y pueden contactar con la firma para más información.
Bronstein, Gewirtz & Grossman은 잠재적인 청구권을 조사하고 있습니다 Liquidia Technologies, Inc. (NASDAQ:LQDA)의 주주를 대신하여. 이 조사는 Liquidia가 2024년 8월 19일에 FDA로부터 잠정 승인을 받았다고 발표한 것을 따른 것으로, 이는 폐동맥 고혈압 및 간질성 폐질환과 관련된 폐 고혈압 치료를 위한 흡입 분말 YUTREPIA™에 대한 것입니다. 그러나 최종 승인이 지연되고 있습니다 경쟁 제품의 규제 독점으로 인해. 이 소식으로 Liquidia의 주가가 30.62% 하락하여 주당 $9.79에 마감했습니다. 주주들은 조사에 도움을 줄 것을 권장하며, 추가 정보를 위해 회사에 연락할 수 있습니다.
Bronstein, Gewirtz & Grossman enquête sur des réclamations potentielles contre Liquidia Technologies, Inc. (NASDAQ:LQDA) au nom de ses actionnaires. L'enquête suit l'annonce de Liquidia le 19 août 2024, selon laquelle la FDA a accordé une approbation provisoire pour YUTREPIA™, leur poudre d'inhalation pour traiter l'hypertension artérielle pulmonaire et l'hypertension pulmonaire associée à des maladies pulmonaires interstitielles. Cependant, l'approbation finale est retardée en raison de l'exclusivité réglementaire d'un produit concurrent. Cette nouvelle a provoqué une chute du prix de l'action de Liquidia de 30,62%, clôturant à 9,79 $ par action. Les actionnaires sont encouragés à participer à l'enquête et peuvent contacter le cabinet pour plus d'informations.
Bronstein, Gewirtz & Grossman ermittelt potenzielle Ansprüche gegen Liquidia Technologies, Inc. (NASDAQ:LQDA) im Namen ihrer Aktionäre. Die Ermittlungen folgen auf die Ankündigung von Liquidia am 19. August 2024, dass die FDA vorläufige Genehmigung für YUTREPIA™, ihr Inhalationspulver zur Behandlung von pulmonaler arterieller Hypertonie und mit interstitieller Lungenerkrankung assoziierter pulmonaler Hypertonie, erteilt hat. Die abschließende Genehmigung verzögert sich jedoch aufgrund der regulatorischen Exklusivität eines konkurrierenden Produkts. Diese Nachrichten führten dazu, dass der Aktienkurs von Liquidia um 30,62% fiel und bei $9,79 pro Aktie schloss. Aktionäre werden ermutigt, an den Ermittlungen mitzuwirken und können die Kanzlei für weitere Informationen kontaktieren.
- FDA granted tentative approval for YUTREPIA™, Liquidia's treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease
- Final FDA approval for YUTREPIA™ is delayed due to a competing product's regulatory exclusivity
- Liquidia's stock price fell 30.62% following the announcement, dropping $4.32 per share to close at $9.79
Insights
The announcement of a legal investigation into Liquidia Technologies raises significant concerns for investors. The 30.62% stock price drop following the FDA's tentative approval of YUTREPIA™ indicates market sensitivity to regulatory challenges. The investigation's focus on potential claims suggests possible securities law violations or undisclosed material information.
Key points to consider:
- The tentative FDA approval, contingent on a competitor's exclusivity expiration, creates uncertainty around YUTREPIA's market entry timeline.
- Potential legal liabilities could impact Liquidia's financial position and future operations.
- Investors should scrutinize the company's disclosures leading up to the FDA announcement for any inconsistencies or omissions.
While the investigation is ongoing, shareholders should closely monitor developments and consider seeking legal advice to understand their rights and potential remedies.
The sharp
Key financial implications:
- Delayed revenue generation from YUTREPIA™ due to regulatory exclusivity issues
- Potential increase in legal expenses related to the ongoing investigation
- Possible impact on future financing options if legal issues persist
Investors should reassess Liquidia's near-term cash flow projections and long-term growth prospects in light of these developments. The company's ability to navigate regulatory hurdles and potential legal challenges will be important for its financial stability and market valuation moving forward.
The FDA's tentative approval of YUTREPIA™ for PAH and PH-ILD treatment is a significant milestone for Liquidia, despite the market's negative reaction. Key considerations:
- YUTREPIA™'s potential to address unmet needs in pulmonary hypertension treatment
- The inhalation powder formulation could offer advantages over existing therapies
- Regulatory exclusivity of competing products suggests a mature market with established treatments
While the delay in final approval is disappointing, the tentative approval indicates that YUTREPIA™ meets FDA's safety and efficacy standards. The critical factor now is the timeline for market entry and Liquidia's strategy to differentiate YUTREPIA™ in a competitive landscape. Long-term prospects remain positive if Liquidia can successfully navigate the regulatory pathway and demonstrate YUTREPIA™'s value proposition to clinicians and patients.
NEW YORK CITY, NY / ACCESSWIRE / August 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Liquidia Technologies, Inc. ("Liquidia" or "the Company") (NASDAQ:LQDA). Investors who purchased Liquidia securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LQDA.
Investigation Details
On August 19, 2024, Liquidia issued a press release announcing that "the U.S. Food and Drug Administration (FDA) has granted tentative approval of YUTREPIA™ (treprostinil) inhalation powder to treat adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD)" but "must await the expiration of regulatory exclusivity of a competing product before final approval can be granted." On this news, Liquidia's stock price fell
What's Next?
If you are aware of any facts relating to this investigation or purchased Liquidia securities, you can assist this investigation by visiting the firm's site: bgandg.com/LQDA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on accesswire.com
FAQ
What is the current investigation against Liquidia Technologies (LQDA) about?
How did Liquidia's (LQDA) stock price react to the FDA's tentative approval announcement?
What is the status of FDA approval for Liquidia's (LQDA) YUTREPIA™ as of August 19, 2024?
What conditions is Liquidia's (LQDA) YUTREPIA™ designed to treat?
